Data also indicated that semaglutide 7.2 mg had a well-tolerated safety profile consistent with semaglutide 2.4 mg and the ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The research firm pointed out that management feels “encouraged” by volumes of Wegovy, Novo Nordisk’s (NYSE:NVO) weight loss ...

Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end ...

Danish pharmaceutical company Novo Nordisk (NVO) on Tuesday said that it has submitted an application to the European ...

A bunch of men have been talking about 'Ozempic penis' as a side-effect of the drug, but an expert has explained the truth ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your ...

Shares of WW International Inc. were climbing in Tuesday trading after the company known as WeightWatchers emerged from bankruptcy and announced a new program to support women as they go through ...

Shares of Novo Nordisk (NYSE:NVO) rose 1% following news that the company has submitted an application to the European Medicines Agency (EMA) to approve a higher dose of its obesity treatment, Wegovy.

Investing.com -- Novo Nordisk (NYSE: NVO) stock rose 1% after the company announced it has submitted an application to the ...